[BREAKING] 95% Effective Moderna COVID-19 Vaccine Tries to Beat Pfizer

In the COVID-19 vaccine race, Pfizer and Moderna's mRNA vaccines both promise high interim results of efficacy against SARS-CoV-2, or the virus that causes the COVID-19 vaccine. 

Now, alongside the shipping of Pfizer and BIoNTech's COVID-19 vaccines across America, another help might come to save humanity against the notorious disease when the United States Food and Drug Administration (FDA) releases detailed analysis of Moderna's mRNA vaccine. 

ALSO READ: Pfizer COVID-19 Vaccine Shows New Results of 95% Effectiveness Against Coronavirus

FDA Findings

(Photo : Maddie Meyer)
A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus (COVID-19) vaccine trials with 600 participants.

NPR reports that the federal agency analysis finds that the vaccine has a favorable safety profile and that there are no specific safety concerns identified that would impede the issuance of Emergency Use Authorization of the vaccine. 

Witf.org adds that the analysis also upholds the vaccine with 95% overall assessing at least two weeks after the second dose of vaccine. They also point out the vaccine shots are given every 28 days. 

However, the New York Post also emphasizes that a 54-page analysis states that the rate of effectiveness in people older than 65 was slightly lower, with only 86.4 percent. 

The federal agency's assessment also states that the two-dose vaccination regimen is highly effective in preventing PCR-confirmed COVID-19 from taking place at least fourteen days after the second dose is received. 

FDA also mentions that the efficacy rate on the company's interim analysis is also consistent throughout various subgroups, including racial and ethnic minorities, elders aging 65 years old, and people who are at risk of severe COVID-19 because of cardiac disease, liver disease, chronic lung disease, obesity, diabetes, mild to severe asthma, and HIV infection. 

READ ALSO: Pfizer's COVID-19 Vaccine: Why It Needs To Be Kept Beyond Freezing Point?

Witf.org reminds that Pfizer's mRNA vaccine was given ok by the federal agency is now being shipped to different states of America, because of the 17-4 votes from the Vaccines and Related Biological Products Advisory Committee. They added that the same committee will discuss the vaccine in an open public meeting. 

The New York Post furthers that the FDA will likely to move rapidly, to grant the emergency approval for Moderna's vaccine just like what happened to Pfizer's mRNA vaccine. Moderna adds in New York Post that by the end of the year, 20 million doses of their vaccine will be available in the United States, enough to be administered to ten million people with 2 doses each. 

Vaccine Requirements

It is known that Pfizer's COVID-19 vaccine needs to be stored in an extremely cold freezer. NPR reports that the required temperature for Pfizer's mRNA vaccine is minus 76 degrees Fahrenheit or colder, adding that Modern's vaccine needs to be frozen too.

However, NPR also states that Modern requires minus 4 degrees Fahrenheit as temperature, compared by the news site to be as cold as a regular freezer at home. 

When the federal agency approves the emergency use of Moderna's COVID-19 vaccine, more Americans will be given a chance to be inoculated and have their immunization against the notorious disease. Another gleam of hope for humanity against the continuous threat of COVID-19. 

READ NEXT: Sacramento Pfizer's COVID-19 Vaccine: Who'll Get the First Wave?

Check out more news and information on COVID-19 and Vaccination on MD News Daily.